About US
Contact us
-
India's per-capita pricing proposal could ripple through emerging marketsThe Indian government's proposal to link drug prices with per capita income could cut some branded drug prices by one-third. That makes some European price cuts look mild. But according to The Eco2012/8/20
-
Lilly takes the lead in DTC ad spending, surpassing PfizerEli Lilly ($LLY) has overtaken Pfizer ($PFE) in the pharma advertising steeplechase. Cegedim Strategic Data reports that Lilly's spending on direct-to-consumer advertising surpassed Pfizer's in Apri2012/8/17
-
U.K. docs don't see sales reps, and don't use pharma's websites, eitherWhile U.S. doctors are seeing more pharma reps with iPads in hand, U.K. doctors are seeing fewer pharma reps, period. According to a recent survey reported at PMLive, more than half of general p2012/8/17
-
New pharma trial: Pfizer, GSK, J&J test 1-page drug information sheetsBy Eric Palmer While drug labels get lots of FDA attention, drug information sheets have gotten very little--until now. With the blessing of the FDA, three of pharma's biggest companies are testi2012/8/16
-
Pfizer to acquire over-the-counter Nexium marketing rights from AstraZenecaPfizer has announced it will acquire exclusive global rights to the over-the-counter (OTC) version of AstraZeneca's Nexium, a heartburn treatment, for $250m. AstraZeneca will retain the rights to man2012/8/16
-
Regulations of strenthening the supervision on pharmaceutical excipients加强药用辅料监督管理的有关规定 Regulations of strengthening the supervision management on pharmaceutical excipients 药用辅料是药品的重要组成部分，直接影响药品的质量。为进一步加强药用 辅料生产、使用的监管，确保药品质量安全，依据《中华人民共和国药品管理法》 及其实施条例、《国务院关于加强食品等产品安2012/8/14
-
NICE stiff-arms Roche melanoma drug once againRoche ($RHHBY) tried to sway the U.K.'s cost-effectiveness watchdogs toward its targeted melanoma drug Zelboraf. But it failed. The National Institute for Health and Clinical Excellence stuck to its r2012/8/14
-
It's official: Pfizer files its animal-health IPOPfizer's ($PFE) animal health unit filed its long-awaited IPO documents. As promised by CEO Ian Read at the end of last month, the newly named Zoetis unit submitted its official go-public plans to t2012/8/14
-
The Dutch Regulatory Agency has declined Cosmo Pharmaceutical's Cortiment drug for the treatment of ulcerative colitis.By Tracy Staton Sanofi wants to know its target audience of consumers with diabetes, and the French drug giant has found that social media in their multiple incarnations serve asuseful windows in2012/8/13
-
Dutch Regulatory Agency rejects Cosmo’s ulcerative colitis drugThe Dutch Regulatory Agency has declined Cosmo Pharmaceutical's Cortiment drug for the treatment of ulcerative colitis.The decision was based on "grounds of clinical relevance", but Cosmo is awaiting2012/8/13